Altimmune (ALT) said Wednesday that data from the phase 2b trial of pemvidutide to treat liver disease demonstrated improvements across non-invasive tests of metabolic dysfunction-associated steatohepatitis activity and fibrosis at 24 weeks compared with placebo.
AI-based pathology showed that pemvidutide treatment led to considerable reductions in fibrosis values compared with placebo, according to a statement.
The company will start patient enrollment for its phase 3 trial of the drug in H2 based on the latest phase 2b results, according to the company.
Price: 2.99, Change: +0.06, Percent Change: +2.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments